Mobile

An eight-week, randomized, double-blind, parallel group, multicenter, dose escalation study to evaluate the efficacy and safety of aliskiren administered alone and in combination with ramipril in pati...

Mise à jour : Il y a 5 ans
Référence : EUCTR2004-001062-40

An eight-week, randomized, double-blind, parallel group, multicenter, dose escalation study to evaluate the efficacy and safety of aliskiren administered alone and in combination with ramipril in patients with hypertension and diabetes mellitus

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objectives of this study are to: • Demonstrate the efficacy of the combination of aliskiren 300 mg and ramipril 10 mg in patients with hypertension and diabetes mellitus by testing the hypothesis of superior reduction in MSDBP from baseline when compared to the component monotherapies. • Compare the efficacy of aliskiren 300 mg to ramipril 10 mg in patients with hypertension and diabetes mellitus by testing the hypothesis that aliskiren monotherapy is non-inferior (or superior) to ramipril 10 mg in MSDBP reduction from baseline.

Critère d'inclusion

  • Hypertension with diabetes mellitus

Liens